NASDAQ: APGE · Biotechnology
Over the past week, Apogee Therapeutics (APGE) racked up 12 mentions across Reddit, X and news, and the read is an Adanos Buy. The crowd averages 75% bullish but is sharply divided: News runs 100% bullish while X sits at just 50%. Wall Street is more cautious, with 1 of 15 analysts rating APGE a buy.
There is little buzz around APGE this week and little agreement on direction, which is why it reads as a Buy.
Wall Street’s 7% buy share sits next to a crowd that ranges from X at 50% to News at 100%. No other tracker puts the two side by side.
15 analysts have weighed in: a Hold consensus: 1 buy call against 0 sell, with an average 12-month price target of $134.62.
The Adanos signal blends each source’s bullish ratio, source breadth, buzz intensity and 3-day momentum. This week bullish sits above the neutral line, momentum is cooling and the 2 sources disagree sharply, so the read is a Buy.
The crowd runs 68 points hotter than the 7% analyst buy share, retail is ahead of the Street here. The split is inside the crowd: News reads 100% bullish while X sits at 50%, a 50-point spread that single-source trackers miss.
Over the 30-day window, Apogee Therapeutics (APGE) buzz held moderate around 49.1 while the price drifted up 0.5% across the period. The chart tracks how social and news attention moved against end-of-day price. Average daily trading volume across the displayed trading days is 1.3M shares. Updated Sep 11, 2026. Over the last 7 trading days, APGE held roughly flat. Buzz activity in the recent week averaged 24.9 and was variable, swinging between 14.0 and 49.1. Recent volume is in line with the 30-day average, reflecting steady institutional and retail participation. Daily crowd sentiment leaned bullish on 3 of the 11 days with directional mentions, shown as the green, grey and red breakdown bars below the chart.
Signal metrics use the latest 7 days; contributor and breadth context uses the 30-day chart window.
No Reddit data for this stock this week.
No Polymarket data for this stock this week.
Query sentiment for APGE and 2001+ stocks from your terminal. Filter by source, timeframe and signal strength.
View CLIEmbed live APGE sentiment on your own site with drop-in web components.
View WidgetsThis week’s sentiment from Adanos, with fundamentals and analyst consensus. A quick-reference snapshot for Sep 11, 2026.
| Adanos signal | Buy |
|---|---|
| Analyst consensus | Hold (1 / 14 / 0) |
| Crowd bullish (7d) | 75% |
| Avg price target | $134.62 |
| Most bullish source | News, 100% |
| Most bearish source | X, 50% |
| Sentiment spread | 50 pts |
| Mentions (7d) | 12 |
| Market cap | $10.22B |
| EPS · Beta | -$4.34 · 0.3 |
| Industry | Biotechnology |
Based on aggregated sentiment from X and News sources, Apogee Therapeutics (APGE) currently carries an Adanos buy signal with 93/100 conviction. The current cross-source average reads 75% bullish across 2 active sources. Those sources contribute 12 tracked mentions over the last 7 days. This is a sentiment-based reading, not financial advice.
The crowd reads bullish on Apogee Therapeutics (APGE), averaging 75% bullish across 2 tracked sources over the last 7 days. The two ends of the range are News at 100% bullish and X at 50%, a 50-point spread. On the professional side, 1 of 15 analysts rate APGE a buy.
Of the 15 analysts covering Apogee Therapeutics (APGE), 1 rate it a buy, 14 a hold and 0 a sell, for a hold consensus. The average price target is $134.62. The crowd is the more bullish of the two, averaging 75%.
Apogee Therapeutics (APGE)'s cross-source average is bullish at 75% bullish. Source readings are split: 1 source leans bullish and 1 source sits at 50% bullish. News reads 100% bullish and x coverage is the most negative at 50% bullish. The combined signal points to broad buy-side pressure with 93/100 conviction.
The cross-source average is bullish for Apogee Therapeutics (APGE) at 75% bullish. Source readings are split: 1 source leans bullish and 1 source sits at 50% bullish. The most bearish reading is x at 50% bullish. 3-day activity momentum is falling across News. The buy signal carries 93/100 conviction.
News is the dominant discussion channel with 10 mentions (83% of total volume). X contributes 2 mentions. The cross-source average is bullish at 75% bullish. Source readings are split: 1 source leans bullish and 1 source sits at 50% bullish.
The Adanos signal blends bullish ratio, buzz score, source breadth and 3-day activity momentum into a single buy/sell reading. APGE's buy signal at 93/100 conviction reflects a bullish cross-source average at 75% bullish. Source readings are split: 1 source leans bullish and 1 source sits at 50% bullish. It is a research shortcut, not financial advice.
The APGE sentiment page is regenerated from the latest 7-day tracking window at each build. Data reflects the most recent Reddit posts, tweets and news articles available in the current publishing cycle.
Peers are ranked first by matching the Buy signal, then by the closest bullish ratio. Discussion activity breaks any remaining ties.
Every data point on this page comes from the Adanos sentiment APIs. Get a free API key and start querying Reddit, X, News and Polymarket sentiment programmatically.
Get Free API Key